Wedbush Securities’s VYNE Therapeutics VYNE Stock Holding History

Wedbush Securities’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-735	Closed	-$92K	–	1024
2020 Q2	$92K	Buy	+735	New	+$99.5K	0.01%	866

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wedbush Securities's VYNE Position: Q3 2020 in Review

Wedbush Securities sold out of VYNE Therapeutics (VYNE) in Q3 2020, closing a stake of 735 shares — an estimated $92K sold.

Wedbush Securities first reported a position in VYNE in Q2 2020 and held it in 1 quarter. The position peaked at $92K in Q2 2020. 105 funds tracked by Wall St. Rank hold VYNE as of Q3 2020.

Wedbush Securities reported no remaining VYNE Therapeutics position as of Q3 2020 after selling out during the quarter.
Wedbush Securities sold 735 VYNE Therapeutics shares in Q3 2020, an estimated $92K.
Wedbush Securities first reported a position in VYNE Therapeutics in Q2 2020 and held it in 1 quarter.
Wedbush Securities's VYNE Therapeutics position peaked at $92K in Q2 2020.
105 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.